Siam Bioscience signs agreement with AstraZeneca to produce and supply potential COVID-19 vaccine for Thailand and Southeast Asian countries
Thai biopharmaceutical company, Siam Bioscience has signed an agreement to partner with AstraZeneca to produce and supply potential COVID-19 vaccine AZD1222 for Thailand and Southeast Asian countries.
Under the agreement, the Thai government and Siam Bioscience will partner with AstraZeneca, the University of Oxford and international agencies such as the World Health Organization to enable global distribution of the potential vaccine, should clinical trials prove successful and regulators approve its use.
Siam Bioscience did not provide any other details on production volumes or the investment sum.
Epygen Biopharma partners with Dyadic to develop COVID-19 vaccine
Epygen Biopharma recently announced that they have partnered with a biotechnology company, Dyadic to co-develop a potential COVID-19 vaccine.
Epygen plans to offer 500 million doses of affordable vaccines within six months of completing the last phase of clinical trials.
Epygen will be joining companies such as Bharat Biotech, Serum Institute of India, and Zydus Cadila in the COVID-19 vaccine race in India.
Biovac is reported to join a vaccine distribution scheme
Biovac was reported to have been in talks with a global COVID-19 vaccine distribution scheme and pharmaceutical companies to produce some of the vaccines the country needs to protect itself against the novel COVID-19 virus.
The Biovac Institute is said to potentially produce up to 30 million doses of COVID-19 vaccines per year, depending on the technology involved.
The Coalition for Epidemic Preparedness Innovations (CEPI), the foundation that co-leads the COVAX scheme alongside the World Health Organization and vaccines alliance GAVI, has identified Biovac as a potential drug product manufacturer but has not signed an agreement yet.
South Africa has also yet to submit a non-binding confirming its intent to participate in the COVAX scheme.